New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 11, 2013
08:05 EDTOREXOrexigen resubmits New Drug Application for Contrave
Orexigen has resubmitted the Contrave New Drug Application to the FDA. Investigational drug Contrave (naltrexone sustained release (SR) / bupropion SR) is being developed for weight loss and maintenance of weight loss.
News For OREX From The Last 14 Days
Check below for free stories on OREX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for OREX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use